MASSDEVICE ON CALL — Biotronik plans to open an Asian headquarters in Singapore as part of a larger commitment to strengthening its presence in the Asia Pacific region, the company announced.
The Berlin-based remote monitoring technology maker expects to launch "full-scale business development in Asia Pacific, which will be coordinated by a highly professional team based out of the new headquarters in Asia," global managing director Dr. Werner Braun said in prepared remarks.
Biotronik touted tripled revenue from Asia Pacific markets in the last 5 years, where it has upwards of 250 employees, according to a press release.
The device maker recently won CE Mark approval in the European Union for its Lumax device, which it called the world’s first and only implantable defibrillator with clearance for use with MRIs.
Biotronik expects its product portfolio, including the Lumax device and the Orsiro drug-eluting stent system, to drive continued short-term growth.
"Biotronik will fully leverage the accelerated development of the Asia Pacific countries to further propel the industry-leading growth trajectory that the company has maintained during previous years despite the global economic downturn," Braun said in a press release. "The economic independence of Biotronik has allowed us to deliver a uniquely sustainable value proposition to our customers—one that includes investment in activities, such as our landmark clinical research program and best-in-class clinical education—in an environment where we have seen our competitors de-investing."
Beaumont announces new med-tech research and training center
Beaumont Health Systems plans to open a hybrid hospital-based medical device research and training lab at its Royal Oak campus in Michigan, Crain’s Detroit Business reported.
Surging diabetes rates in India create a run for dialysis
American Medical Assn. calls for permanent doc fix
The American Medical Assn. called for a permanent repeal of the Medicare payment formula that has frequently raised the spectre of cuts in physician reimbursements, according to Healthwatch.
Prostate screenings fail to dampen death rate
Annual prostate tumors raised detection rates but did little to stem deaths related to prostate cancer, HemOnctoday.com reported.